{"id":60795,"date":"2024-02-28T07:08:53","date_gmt":"2024-02-28T07:08:53","guid":{"rendered":"https:\/\/medsname.com\/atrest\/"},"modified":"2026-05-01T10:49:16","modified_gmt":"2026-05-01T10:49:16","slug":"atrest","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/atrest\/","title":{"rendered":"Atrest"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 Rychl\u00e1 odpov\u011b\u010f \u2014 Co je Atrest?<\/h3>\n

Atrest<\/strong> je peror\u00e1ln\u00ed tetrabenazin<\/strong> (12,5 mg) tableta \u2014 inhibitor VMAT2 (vezikul\u00e1rn\u00edho monoaminov\u00e9ho transport\u00e9ru 2)<\/strong> schv\u00e1len\u00fd speci\u00e1ln\u011b pro l\u00e9\u010dbu chorey spojen\u00e9 s Huntingtonovou chorobou<\/strong>. P\u016fsob\u00ed sn\u00ed\u017een\u00edm hladiny dopaminu v nervov\u00fdch zakon\u010den\u00edch, \u010d\u00edm\u017e omezuje mimovoln\u00ed kroutiv\u00e9 a trhav\u00e9 pohyby typick\u00e9 pro Huntingtonovu choreu. Po\u010d\u00e1te\u010dn\u00ed d\u00e1vka: 12,5 mg jednou denn\u011b<\/strong>, zvy\u0161ovan\u00e1 t\u00fddn\u011b o 12,5 mg a\u017e na maximum 37,5 mg\/d\u00e1vka (75\u2013100 mg\/den)<\/strong>, v\u017edy rozd\u011bleno do 2\u20133 d\u00e1vek. Pacienti p\u0159ij\u00edmaj\u00edc\u00ed >50 mg\/den vy\u017eaduj\u00ed genotypizaci CYP2D6<\/strong>. B\u011b\u017en\u00e9 vedlej\u0161\u00ed \u00fa\u010dinky: sedace, akathisie, deprese, parkinsonismus, nespavost. \u010cern\u00e9 varov\u00e1n\u00ed:<\/strong> zvy\u0161uje riziko deprese a sebevra\u017eednosti u pacient\u016f s Huntingtonovou chorobou \u2014 pe\u010dliv\u011b sledujte n\u00e1ladu.<\/p>\n<\/div>\n

\nCo z\u00edsk\u00e1te s MedsBase:<\/strong> V\u00fdrobce certifikovan\u00fd WHO-GMP \u00b7 Diskr\u00e9tn\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 doprava \u00b7 V\u00edce ne\u017e 1 400 ov\u011b\u0159en\u00fdch recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a>\n<\/div>\n

\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n

Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n

Na\u0161e generick\u00e9 l\u00e9ky poch\u00e1zej\u00ed od v\u00fdrobc\u016f certifikovan\u00fdch WHO-GMP a jsou expedov\u00e1ny po cel\u00e9m sv\u011bt\u011b v diskr\u00e9tn\u00edm, nen\u00e1padn\u00e9m balen\u00ed \u2013 na vn\u011bj\u0161\u00ed stran\u011b bal\u00edku nen\u00ed uveden n\u00e1zev l\u00e9ku. Platby kartou jsou sm\u011brov\u00e1ny prost\u0159ednictv\u00edm regulovan\u00e9ho procesoru (popisky na v\u00fdpisu zahrnuj\u00ed regulovan\u00e9ho procesora plateb kartou \u2013 nikdy \u201cMedsBase\u201d nebo n\u00e1zev l\u00e9ku). P\u0159ij\u00edm\u00e1me tak\u00e9 kryptom\u011bny a bankovn\u00ed p\u0159evody SEPA. Ka\u017ed\u00e1 objedn\u00e1vka je zaji\u0161t\u011bna na\u0161\u00ed politikou p\u0159eposl\u00e1n\u00ed.<\/p>\n

Co je Atrest?<\/h2>\n

Atrest je peror\u00e1ln\u00ed tableta obsahuj\u00edc\u00ed tetrabenazin 12,5 mg<\/strong>. Tetrabenazin je inhibitor vezikul\u00e1rn\u00edho monoaminov\u00e9ho transport\u00e9ru 2 (VMAT2)<\/strong> \u2014 prvn\u00ed l\u00e9k speci\u00e1ln\u011b schv\u00e1len\u00fd pro l\u00e9\u010dbu chorey spojen\u00e9 s Huntingtonovou chorobou<\/strong>.<\/p>\n

Deplece presynaptick\u00fdch z\u00e1sob dopaminu tetrabenazinem sni\u017euje mimovoln\u00e9, tane\u010dn\u00ed pohyby (chorea), kter\u00e9 charakterizuj\u00ed Huntingtonovu chorobu, bez rizika tardivn\u00ed dyskineze spojen\u00e9ho s tradi\u010dn\u00edmi blok\u00e1tory dopaminov\u00fdch receptor\u016f. Poprv\u00e9 byl pou\u017e\u00edv\u00e1n v Evrop\u011b v 70. letech a z\u00edskal schv\u00e1len\u00ed FDA v roce 2008 jako Xenazine<\/strong>. Atrest je vyr\u00e1b\u011bn ve za\u0159\u00edzen\u00ed certifikovan\u00e9m WHO-GMP a je bioekvivalentn\u00ed k origin\u00e1ln\u00ed zna\u010dce ve stejn\u00e9 s\u00edle.<\/p>\n

Jak funguje Atrest (Tetrabenazin)?<\/h2>\n

Tetrabenazine ireverzibiln\u011b inhibuje VMAT2<\/strong>, protein zodpov\u011bdn\u00fd za balen\u00ed dopaminu, serotoninu a noradrenalinu do synaptick\u00fdch vezikul. Blokov\u00e1n\u00edm VMAT2 l\u00e9k vy\u010derp\u00e1v\u00e1 presynaptick\u00e9 z\u00e1soby monoamin\u016f \u2013 p\u0159edev\u0161\u00edm dopaminu v baz\u00e1ln\u00edch gangli\u00edch. Nadm\u011brn\u00e1 dopaminergn\u00ed aktivita ve striatu je hlavn\u00ed p\u0159\u00ed\u010dinou choreiformn\u00edch pohyb\u016f u Huntingtonovy choroby, proto sn\u00ed\u017een\u00ed dostupnosti dopaminu na postsynaptick\u00e9m receptoru p\u0159\u00edmo potla\u010duje choreu.<\/p>\n

L\u00e9k je v\u00fdrazn\u011b metabolizov\u00e1n CYP2D6 na dva aktivn\u00ed metabolity (\u03b1-HTBZ a \u03b2-HTBZ), kter\u00e9 jsou zodpov\u011bdn\u00e9 za v\u011bt\u0161inu klinick\u00e9ho \u00fa\u010dinku. Pomal\u00ed metaboliz\u00e1to\u0159i CYP2D6<\/strong> maj\u00ed v\u00fdrazn\u011b vy\u0161\u0161\u00ed plazmatick\u00e9 hladiny, proto je p\u0159ed p\u0159ekro\u010den\u00edm d\u00e1vky 50 mg\/den nutn\u00e9 genotypov\u00e1n\u00ed.<\/p>\n

D\u00e1vkov\u00e1n\u00ed a pod\u00e1v\u00e1n\u00ed<\/h2>\n\n\n\n\n\n\n\n\n
T\u00fdden<\/th>\nDenn\u00ed d\u00e1vka<\/th>\nD\u00e1vkovac\u00ed sch\u00e9ma<\/th>\n<\/tr>\n<\/thead>\n
T\u00fdden 1<\/td>\n12,5 mg<\/td>\nJednou denn\u011b (r\u00e1no)<\/td>\n<\/tr>\n
T\u00fdden 2<\/td>\n25 mg<\/td>\n12,5 mg dvakr\u00e1t denn\u011b<\/td>\n<\/tr>\n
3. t\u00fdden a v\u00edce<\/td>\n37,5\u201350 mg<\/td>\nRozd\u011bleno do 2\u20133 d\u00e1vek<\/td>\n<\/tr>\n
Maxim\u00e1ln\u011b<\/td>\n75\u2013100 mg\/den*<\/td>\n*Genotypov\u00e1n\u00ed CYP2D6 vy\u017eadov\u00e1no p\u0159i d\u00e1vk\u00e1ch >50 mg\/den<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

U\u017e\u00edvejte s j\u00eddlem nebo bez j\u00eddla. \u017d\u00e1dn\u00e1 jednotliv\u00e1 d\u00e1vka by nem\u011bla p\u0159ekro\u010dit 37,5 mg.<\/strong> Pokud je l\u00e9\u010dba p\u0159eru\u0161ena na >5 dn\u00ed, op\u011btovn\u011b titrujte od 12,5 mg.<\/p>\n

Vedlej\u0161\u00ed \u00fa\u010dinky<\/h2>\n
\u26a0 \u010cern\u00e1 sk\u0159\u00ed\u0148ka varov\u00e1n\u00ed \u2014 Deprese a suicid\u00e1ln\u00ed chov\u00e1n\u00ed:<\/strong> Tetrabenazin zvy\u0161uje riziko deprese a sebevra\u017eedn\u00fdch my\u0161lenek\/chov\u00e1n\u00ed u pacient\u016f s Huntingtonovou chorobou. Nepou\u017e\u00edvejte u pacient\u016f, kte\u0159\u00ed jsou aktivn\u011b sebevra\u017eedn\u00ed nebo maj\u00ed nel\u00e9\u010denou\/nedostate\u010dn\u011b l\u00e9\u010denou depresi. Pacienti a pe\u010dovatel\u00e9 by m\u011bli b\u00fdt upozorn\u011bni na nutnost sledovat vznik nebo zhor\u0161en\u00ed deprese, suicid\u00e1ln\u00edho chov\u00e1n\u00ed nebo neobvykl\u00fdch zm\u011bn v chov\u00e1n\u00ed.<\/div>\n

\u010cast\u00e9 (\u226510 %):<\/strong> sedace\/ospalost, \u00fanava, nespavost, deprese, akatizie (neklid), \u00fazkost, nevolnost.<\/p>\n

Z\u00e1va\u017en\u00e9:<\/strong> parkinsonismus (d\u00e1vkov\u011b z\u00e1visl\u00fd), neuroleptick\u00fd malign\u00ed syndrom (vz\u00e1cn\u011b), prodlou\u017een\u00ed QTc intervalu (vyvarovat se u vrozen\u00e9ho dlouh\u00e9ho QT syndromu), dysfagie (zv\u00fd\u0161en\u00e9 riziko aspirace u pacient\u016f s Huntingtonovou chorobou).<\/p>\n

Varov\u00e1n\u00ed a opat\u0159en\u00ed<\/h2>\n